Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01406145 · ClinicalTrials.gov registry record · Phase 1

A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil

A Phase 1 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target

NCT01406145 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01406145, a Phase 1 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target

Study Summary

This study is intended to determine the safety and tolerability of ASP0777 in subjects with Alzheimer's Disease (AD) taking a stable dose of donepezil.

Interventions

  • DRUG Placebo
  • DRUG ASP0777

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2011-06-16
Est. Completion 2011-11-04
Phase Phase 1

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT01406145

The ClinicalTrials.gov registry entry for NCT01406145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01406145 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01406145 about?

NCT01406145 is a clinical study titled "A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil". This study is intended to determine the safety and tolerability of ASP0777 in subjects with Alzheimer's Disease (AD) taking a stable dose of donepezil.

What is the current status of trial NCT01406145?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-06-16. Estimated completion is 2011-11-04.

What interventions are being tested in trial NCT01406145?

The interventions under investigation include: Placebo (DRUG), ASP0777 (DRUG).

Who is sponsoring clinical trial NCT01406145?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.